Mirtazapine alters cue-associated methamphetamine seeking in rats

Steven M. Graves, T. Celeste Napier

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Methamphetamine (METH) is a potent psychostimulant, repeated use of which can result in a substance abuse disorder. Withdrawn individuals are highly prone to relapse, which may be driven, at least in part, by a hyperresponsivity to METH-associated cues that can prompt METH-seeking. Clinically efficacious pharmacotherapies for METH abuse are critically needed. Mirtazapine (Remeron) is an atypical antidepressant that antagonizes activated norepinephrine α2, histamine 1 serotonin (5-HT) 2A/C, and 5-HT 3 receptors. This pharmacologic profile prompted our interest in its potential for preventing relapse to METH-taking. This study tested the hypothesis that mirtazapine would attenuate METH-seeking in rats trained to self-administer METH. Methods: Rats were trained to self-administer METH in a lever-pressing operant task. The effect of mirtazapine on METH-seeking was determined by evaluating lever pressing in the presence of cues previously associated with METH, but in the absence of METH reinforcement. Two paradigms were used: cue reactivity, wherein rats do not undergo extinction training, and a cue-induced reinstatement paradigm after extinction. Results: Mirtazapine (5.0 mg/kg) pretreatment reduced METH-seeking by ∼ 50% in the first 15 min of cue reactivity and cue-induced reinstatement testing. This mirtazapine dose did not significantly affect motor performance. Conclusions: This study revealed the overlapping nature of cue reactivity and cue-induced reinstatement procedures and provided preclinical evidence that mirtazapine can attenuate METH-seeking behavior.

Original languageEnglish (US)
Pages (from-to)275-281
Number of pages7
JournalBiological Psychiatry
Volume69
Issue number3
DOIs
StatePublished - Feb 1 2011

Fingerprint

Methamphetamine
Cues
mirtazapine
Serotonin
Second-Generation Antidepressive Agents
Recurrence
Serotonin Receptors
Histamine
Substance-Related Disorders
Norepinephrine

Keywords

  • Atypical antidepressant
  • cue reactivity
  • methamphetamine
  • reinstatement
  • self-administration

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Graves, Steven M. ; Napier, T. Celeste. / Mirtazapine alters cue-associated methamphetamine seeking in rats. In: Biological Psychiatry. 2011 ; Vol. 69, No. 3. pp. 275-281.
@article{77129f869f8444299d806751db25bdd9,
title = "Mirtazapine alters cue-associated methamphetamine seeking in rats",
abstract = "Background: Methamphetamine (METH) is a potent psychostimulant, repeated use of which can result in a substance abuse disorder. Withdrawn individuals are highly prone to relapse, which may be driven, at least in part, by a hyperresponsivity to METH-associated cues that can prompt METH-seeking. Clinically efficacious pharmacotherapies for METH abuse are critically needed. Mirtazapine (Remeron) is an atypical antidepressant that antagonizes activated norepinephrine α2, histamine 1 serotonin (5-HT) 2A/C, and 5-HT 3 receptors. This pharmacologic profile prompted our interest in its potential for preventing relapse to METH-taking. This study tested the hypothesis that mirtazapine would attenuate METH-seeking in rats trained to self-administer METH. Methods: Rats were trained to self-administer METH in a lever-pressing operant task. The effect of mirtazapine on METH-seeking was determined by evaluating lever pressing in the presence of cues previously associated with METH, but in the absence of METH reinforcement. Two paradigms were used: cue reactivity, wherein rats do not undergo extinction training, and a cue-induced reinstatement paradigm after extinction. Results: Mirtazapine (5.0 mg/kg) pretreatment reduced METH-seeking by ∼ 50{\%} in the first 15 min of cue reactivity and cue-induced reinstatement testing. This mirtazapine dose did not significantly affect motor performance. Conclusions: This study revealed the overlapping nature of cue reactivity and cue-induced reinstatement procedures and provided preclinical evidence that mirtazapine can attenuate METH-seeking behavior.",
keywords = "Atypical antidepressant, cue reactivity, methamphetamine, reinstatement, self-administration",
author = "Graves, {Steven M.} and Napier, {T. Celeste}",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.biopsych.2010.09.032",
language = "English (US)",
volume = "69",
pages = "275--281",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "3",

}

Mirtazapine alters cue-associated methamphetamine seeking in rats. / Graves, Steven M.; Napier, T. Celeste.

In: Biological Psychiatry, Vol. 69, No. 3, 01.02.2011, p. 275-281.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mirtazapine alters cue-associated methamphetamine seeking in rats

AU - Graves, Steven M.

AU - Napier, T. Celeste

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background: Methamphetamine (METH) is a potent psychostimulant, repeated use of which can result in a substance abuse disorder. Withdrawn individuals are highly prone to relapse, which may be driven, at least in part, by a hyperresponsivity to METH-associated cues that can prompt METH-seeking. Clinically efficacious pharmacotherapies for METH abuse are critically needed. Mirtazapine (Remeron) is an atypical antidepressant that antagonizes activated norepinephrine α2, histamine 1 serotonin (5-HT) 2A/C, and 5-HT 3 receptors. This pharmacologic profile prompted our interest in its potential for preventing relapse to METH-taking. This study tested the hypothesis that mirtazapine would attenuate METH-seeking in rats trained to self-administer METH. Methods: Rats were trained to self-administer METH in a lever-pressing operant task. The effect of mirtazapine on METH-seeking was determined by evaluating lever pressing in the presence of cues previously associated with METH, but in the absence of METH reinforcement. Two paradigms were used: cue reactivity, wherein rats do not undergo extinction training, and a cue-induced reinstatement paradigm after extinction. Results: Mirtazapine (5.0 mg/kg) pretreatment reduced METH-seeking by ∼ 50% in the first 15 min of cue reactivity and cue-induced reinstatement testing. This mirtazapine dose did not significantly affect motor performance. Conclusions: This study revealed the overlapping nature of cue reactivity and cue-induced reinstatement procedures and provided preclinical evidence that mirtazapine can attenuate METH-seeking behavior.

AB - Background: Methamphetamine (METH) is a potent psychostimulant, repeated use of which can result in a substance abuse disorder. Withdrawn individuals are highly prone to relapse, which may be driven, at least in part, by a hyperresponsivity to METH-associated cues that can prompt METH-seeking. Clinically efficacious pharmacotherapies for METH abuse are critically needed. Mirtazapine (Remeron) is an atypical antidepressant that antagonizes activated norepinephrine α2, histamine 1 serotonin (5-HT) 2A/C, and 5-HT 3 receptors. This pharmacologic profile prompted our interest in its potential for preventing relapse to METH-taking. This study tested the hypothesis that mirtazapine would attenuate METH-seeking in rats trained to self-administer METH. Methods: Rats were trained to self-administer METH in a lever-pressing operant task. The effect of mirtazapine on METH-seeking was determined by evaluating lever pressing in the presence of cues previously associated with METH, but in the absence of METH reinforcement. Two paradigms were used: cue reactivity, wherein rats do not undergo extinction training, and a cue-induced reinstatement paradigm after extinction. Results: Mirtazapine (5.0 mg/kg) pretreatment reduced METH-seeking by ∼ 50% in the first 15 min of cue reactivity and cue-induced reinstatement testing. This mirtazapine dose did not significantly affect motor performance. Conclusions: This study revealed the overlapping nature of cue reactivity and cue-induced reinstatement procedures and provided preclinical evidence that mirtazapine can attenuate METH-seeking behavior.

KW - Atypical antidepressant

KW - cue reactivity

KW - methamphetamine

KW - reinstatement

KW - self-administration

UR - http://www.scopus.com/inward/record.url?scp=78650848929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650848929&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2010.09.032

DO - 10.1016/j.biopsych.2010.09.032

M3 - Article

VL - 69

SP - 275

EP - 281

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 3

ER -